{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:02:59Z","timestamp":1794204179987,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Purpose: The combination of a mammalian target of rapamycin inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase 1 study in advanced solid tumour patients to assess safety, efficacy and pharmacodynamic (PD) outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We employed a 3+3 dose escalation design to establish the safety and recommended phase 2 doses (RP2D) of daily everolimus and lenalidomide in patients with advanced solid tumours. The starting doses were 5 and 10\u2009mg, respectively, with planned escalation to maximum single-agent doses of 10 and 25\u2009mg in the absence of dose-limiting toxicity. PD endpoints of lymphocyte subsets and immune cytokines were assessed in peripheral blood using multiparameter flow cytometry and LUMINEX assay. Efficacy was evaluated by cross-sectional imaging after every two cycles of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled 44 patients, median age of 58 years and 28 males (63.6%). The RP2D was established as 10 and 25\u2009mg daily continuously for everolimus and lenalidomide. Common (&gt;5%) grade \u22653 adverse events included rash (19%), neutropenia (19%), hypokalaemia (11%) and fatigue (9%). Best efficacy outcomes in 36 evaluable patients were partial response in 5 (13.8%), stable disease in 24 (55.8%) and progressive disease in 7 (19.4%) patients. PD assessment revealed significant association of cytokine levels (interleukin-2 (IL2), IL21 and IL17), baseline activated and total CD8+ lymphocytes and change in B cell lymphocytes and activated NK cells with clinical benefit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study demonstrated the safety of everolimus and lenalidomide with promising efficacy signal in thyroid and adenoid cystic cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical Trial Registration<\/jats:title>\n                <jats:p>NCT01218555<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0988-2","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T23:04:55Z","timestamp":1595545495000},"page":"1228-1234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma"],"prefix":"10.1038","volume":"123","author":[{"given":"R. Donald","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Carthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor E.","family":"Steuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadlo R.","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-7728","authenticated-orcid":false,"given":"Taofeek K.","family":"Owonikoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"988_CR1","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271\u20132281 (2007).","journal-title":"N. Engl. J. Med."},{"key":"988_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473\u20131482 (2015).","journal-title":"Lancet Oncol."},{"key":"988_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","volume":"16","author":"SA Hurvitz","year":"2015","unstructured":"Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 16, 816\u2013829 (2015).","journal-title":"Lancet Oncol."},{"key":"988_CR4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Horsch, D., Winkler, R. E. et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378, 2005\u20132012 (2011).","journal-title":"Lancet"},{"key":"988_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"988_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"988_CR7","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2012.599","volume":"32","author":"J Shortt","year":"2013","unstructured":"Shortt, J., Hsu, A. K. & Johnstone, R. W. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191\u20134202 (2013).","journal-title":"Oncogene"},{"key":"988_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B. et al. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2, 36 (2009).","journal-title":"J. Hematol. Oncol."},{"key":"988_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/COC.0b013e31815e451f","volume":"31","author":"RJ Amato","year":"2008","unstructured":"Amato, R. J., Hernandez-McClain, J., Saxena, S. & Khan, M. Lenalidomide therapy for metastatic renal cell carcinoma. Am. J. Clin. Oncol. 31, 244\u2013249 (2008).","journal-title":"Am. J. Clin. Oncol."},{"key":"988_CR10","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052\u20137058 (2005).","journal-title":"Cancer Res."},{"key":"988_CR11","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1158\/0008-5472.CAN-08-1522","volume":"68","author":"X Wang","year":"2008","unstructured":"Wang, X., Yue, P., Kim, Y. A., Fu, H., Khuri, F. R. & Sun, S. Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR\/raptor inhibition-initiated, mTOR\/rictor-independent Akt activation. Cancer Res. 68, 7409\u20137418 (2008).","journal-title":"Cancer Res."},{"key":"988_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.molcel.2011.08.029","volume":"44","author":"Y Zhao","year":"2011","unstructured":"Zhao, Y., Xiong, X. & Sun, Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol. Cell 44, 304\u2013316 (2011).","journal-title":"Mol. Cell"},{"key":"988_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1593\/neo.12532","volume":"14","author":"Y Zhao","year":"2012","unstructured":"Zhao, Y. & Sun, Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia 14, 360\u2013367 (2012).","journal-title":"Neoplasia"},{"key":"988_CR14","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","volume":"104","author":"N Raje","year":"2004","unstructured":"Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C. et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188\u20134193 (2004).","journal-title":"Blood"},{"key":"988_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13046-016-0327-x","volume":"35","author":"Z Jin","year":"2016","unstructured":"Jin, Z., Qing, K., Ouyang, Y., Liu, Z., Wang, W., Li, X. et al. Low dose of lenalidmide and PI3K\/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res. 35, 52 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"988_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/cncr.27937","volume":"119","author":"TK Owonikoko","year":"2013","unstructured":"Owonikoko, T. K., Hossain, M. S., Bhimani, C., Chen, Z., Kim, S., Ramalingam, S. S. et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 119, 1503\u20131511 (2013).","journal-title":"Cancer"},{"key":"988_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjh.12909","volume":"166","author":"AJ Yee","year":"2014","unstructured":"Yee, A. J., Hari, P., Marcheselli, R., Mahindra, A. K., Cirstea, D. D., Scullen, T. A. et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br. J. Haematol. 166, 401\u2013409 (2014).","journal-title":"Br. J. Haematol."},{"key":"988_CR18","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1200\/JCO.2010.32.4962","volume":"29","author":"CC Hofmeister","year":"2011","unstructured":"Hofmeister, C. C., Yang, X., Pichiorri, F., Chen, P., Rozewski, D. M., Johnson, A. J. et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J. Clin. Oncol. 29, 3427\u20133434 (2011).","journal-title":"J. Clin. Oncol."},{"key":"988_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/annonc\/mdv537","volume":"27","author":"SJ Wong","year":"2016","unstructured":"Wong, S. J., Karrison, T., Hayes, D. N., Kies, M. S., Cullen, K. J., Tanvetyanon, T. et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann. Oncol. 27, 318\u2013323 (2016).","journal-title":"Ann. Oncol."},{"key":"988_CR20","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1002\/cncr.25852","volume":"117","author":"A Argiris","year":"2011","unstructured":"Argiris, A., Ghebremichael, M., Burtness, B., Axelrod, R. S., Deconti, R. C. & Forastiere, A. A. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 117, 3374\u20133382 (2011).","journal-title":"Cancer"},{"key":"988_CR21","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","volume":"24","author":"SM Lim","year":"2013","unstructured":"Lim, S. M., Chang, H., Yoon, M. J., Hong, Y. K., Kim, H., Chung, W. Y. et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann. Oncol. 24, 3089\u20133094 (2013).","journal-title":"Ann. Oncol."},{"key":"988_CR22","doi-asserted-by":"publisher","unstructured":"Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J., Gelderblom, H. et al. Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/jc.2016-2525 (2016).","DOI":"10.1210\/jc.2016-2525"},{"key":"988_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cei.12343","volume":"177","author":"A Busch","year":"2014","unstructured":"Busch, A., Zeh, D., Janzen, V., Mugge, L. O., Wolf, D., Fingerhut, L. et al. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin. Exp. Immunol. 177, 439\u2013453 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"988_CR24","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A. et al. Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"988_CR25","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","volume":"57","author":"D Zhu","year":"2008","unstructured":"Zhu, D., Corral, L. G., Fleming, Y. W. & Stein, B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57, 1849\u20131859 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"988_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11095-012-0909-z","volume":"30","author":"DK Pawaskar","year":"2013","unstructured":"Pawaskar, D. K., Straubinger, R. M., Fetterly, G. J., Ma, W. W. & Jusko, W. J. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharm. Res. 30, 707\u2013713 (2013).","journal-title":"Pharm. Res."},{"key":"988_CR27","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-15-0749","volume":"76","author":"F Housseau","year":"2016","unstructured":"Housseau, F., Wu, S., Wick, E. C., Fan, H., Wu, X., Llosa, N. J. et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res. 76, 2115\u20132124 (2016).","journal-title":"Cancer Res."},{"key":"988_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00262-017-1970-6","volume":"66","author":"V Kannappan","year":"2017","unstructured":"Kannappan, V., Butcher, K., Trela, M., Nicholl, I., Wang, W. & Attridge, K. Interleukin 21 inhibits cancer-mediated FOXP3 induction in naive human CD4 T cells. Cancer Immunol. Immunother. 66, 637\u2013645 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"988_CR29","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-15-2273","volume":"22","author":"V Phan-Lai","year":"2016","unstructured":"Phan-Lai, V., Dang, Y., Gad, E., Childs, J. & Disis, M. L. The antitumor efficacy of IL2\/IL21-cultured polyfunctional neu-specific T cells is TNFalpha\/IL17 dependent. Clin. Cancer Res. 22, 2207\u20132216 (2016).","journal-title":"Clin. Cancer Res."},{"key":"988_CR30","doi-asserted-by":"publisher","first-page":"696578","DOI":"10.1155\/2015\/696578","volume":"2015","author":"M Croce","year":"2015","unstructured":"Croce, M., Rigo, V. & Ferrini, S. IL-21: a pleiotropic cytokine with potential applications in oncology. J. Immunol. Res. 2015, 696578 (2015).","journal-title":"J. Immunol. Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0988-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:17Z","timestamp":1684616957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0988-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10,13]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0988-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Emory University IRB. All participants provided informed consent and the study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All relevant data pertaining to this study are included in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"T.K.O. served on a paid advisory board for Novartis Oncology and Celgene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by Celgene Inc. with funding and free supply of lenalidomide and by Novartis Oncology with free supply of everolimus. Additional support in part by NIH\/NCI 5K23CA164015 grant award (PI: T.K.O.). Research reported in this publication was also supported, in part, by the Biostatistics and Bioinformatics Shared resource of Winship Cancer Institute of Emory University and National Cancer Institute at the National Institutes of Health under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}